We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

097950:KRXCJ Cheiljedang Corporation Analysis

Data as of 2026-05-31 - not real-time

₩202,000.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

The stock is trading near a key support level, with the RSI firmly in oversold territory. MACD momentum remains bearish, widening the histogram gap. A modest beta suggests limited sensitivity to broader market swings, yet 30‑day volatility is notably high. The forward P/E sits at a modest multiple, but the current price sits well above the DCF‑derived fair value. The Fear & Greed gauge is perched in the “Extreme Greed” zone, hinting at potential sentiment‑driven overpricing. Together, these signals paint a picture of a stock that may be vulnerable to a short‑term correction despite the technical oversold hint.
On the fundamentals side, revenue growth is modest and profit margins remain negative, while debt levels are more than double equity. The dividend yield is attractive, but a payout ratio exceeding 100 % raises questions about sustainability. The defensive consumer sector provides a cushion against cyclical downturns, yet regulatory and geographic exposures add medium‑level risk. Liquidity appears to be weakening, as volume trends are decreasing. Given the overvalued pricing relative to intrinsic estimates, a cautious stance is warranted. Investors should monitor earnings momentum and any improvement in cash generation before committing further capital.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Oversold RSI suggests possible rebound
  • Proximity to support level limits downside
  • Bearish MACD may delay recovery

Medium Term

1–3 years
Cautious
Model confidence: 7/10

Key Factors

  • Current price exceeds DCF fair value
  • High debt-to-equity ratio strains balance sheet
  • Dividend payout unsustainable

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Diversified product portfolio in biotech and food
  • Defensive consumer sector offers stability
  • Long‑term dividend attractiveness if payout improves

Key Metrics & Analysis

Financial Health

Revenue Growth6.00%
Profit Margin-1.81%
P/E Ratio6.9
ROE-0.96%
ROA2.41%
Debt/Equity103.50
Op. Cash Flow₩2674.4B
Free Cash Flow₩660.9B

Technical Analysis

TrendNeutral
RSI34.7
Support₩199,300.00
Resistance₩252,000.00
MA 20₩221,475.00
MA 50₩224,450.00
MA 200₩222,719.00
MACDBearish
VolumeDecreasing
Fear & Greed Index94.07

Valuation

Fair Value₩68,984.40
Target Price₩273,250.00
Upside/Downside35.27%
GradeOvervalued
TypeValue
Dividend Yield2.97%

Risk Assessment

Beta0.52
Volatility44.03%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.